RecruitingNot Applicable

A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease

China250 participantsStarted 2024-01-01

Plain-language summary

This study will explore the safety and efficacy of BASIS technology in ICAS-LVO lesions through a multicenter, prospective, registry, observational single-arm study.By registering intraoperative recanalization using this technique time, recanalization grade, operative thrombectomy times, intraoperative complications perforating branch occlusion, vascular dissection, vascular rupture, Ectopic thrombus, probability of symptomatic intracranial hemorrhage, mRS Score and mortality rate were followed up for 3 months The unique advantages of the application of the assessment BASIS in this type of lesion provide new insights into complex lesions such as ICAS-LVO The thought and operation method can shorten the operation time, improve the good prognosis, reduce the economic burden and reduce the operation Complications make a positive contribution to ensure that patients receive safe, effective and precise treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years old; * Ischemic stroke; * Within 72 hours from the onset of symptoms to the time of visit, including post-awakening stroke or blindness For stroke patients, the time when symptoms start is defined as "the last normal time"; * Neuroimaging examination indicated occlusion of anterior or posterior intracranial large vessels, TOAST type was large atherosclerosis type. * BASIS technique was used for intravascular therapy. Exclusion Criteria: * Neuroimaging findings on admission, acute occlusion of multiple vessels and tandem lesions; * History of atrial fibrillation or heart valve surgery; * There are clinical contraindications to the use of antiplatelet drugs (hemophilia or thrombocytopenia).Rare disease, known history of coagulation disorders, platelet abnormalities; There is active internal bleeding, intracranial Bleeding history, arteriovenous malformation, aneurysm, etc.); * Other types of stroke, including hemorrhagic stroke.

What they're measuring

mRS scores at 90 days

Timeframe: 90 days

FPE:first pass effect

Timeframe: From enrollment to the end of the surgery about 3 hours

Trial details

NCT IDNCT06881420

SponsorFujian Medical University Union Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31